Carbohydrate-deficient glycoprotein syndrome type I (CDG1) is an autosomal recessive, metabolic disorder with severe psychomotor retardation and a high mortality rate in early childhood. Most patients have a deficiency of phosphomannomutase, due to mutations in PMM2, a gene located on chromosome 16p13. Over a period of 18 months we offered prenatal diagnosis to eight families. In six cases and prior to the identification of the gene, the diagnosis was based on linkage analysis and phosphomannomutase measurements. Subsequently direct mutation analysis has been used in two families. It is shown here that phosphomannomutase activities are strongly reduced in cultured amniocytes and trophoblasts of affected foetuses. We refrained from offering prenatal testing in two other families, because either the disease did not link to chromosome 16 and/or normal phosphomannomutase activities were measured in fibroblasts from the proband. This confirms earlier suggestions of heterogeneity for CDG1.
Introduction
Carbohydrate-deficient glycoprotein syndrome type I (CDG1) or Jaeken disease (OMIM 212065) is a genetic multi-system syndrome. At birth, the patients have a peculiar abnormal distribution of subcutaneous fat and nipple retraction. There is encephalopathy with axial hypotonia, abnormal eye movements, internal strabismus, pronounced psychomotor retardation without regression, as well as peripheral neuropathy, cerebellar hypoplasia and retinitis pigmentosa. Severe infections, liver insufficiency or cardiomyopathy lead to 20% lethality in the first years of life. 1, 2 The disease is associated with defective glycosylation of glycoconjugates. [3] [4] [5] [6] The diagnosis of CDG1 has classically been based on the abnormal pattern which is observed after iso-electric focusing (IEF) of serum transferrins. 3, 4 Unfortunately, the transferrin assay does not reveal an aberrant pattern in amniotic fluid or in foetal blood. 7, 8 Since the CDG1 locus has been mapped to chromosome 16p, 9 prenatal diagnosis has become possible by linkage analysis. However, a major concern has arisen with the identification of genetic heterogeneity in CDG1. It was initially shown that the disease did not link to chromosome 16p13 in a family with two affected siblings, 10 and we describe another case in the present report. Obviously, a prenatal test with linked genetic markers on chromosome 16p is of no value in such cases.
In 1995, Van Schaftingen and Jaeken identified a deficiency of phosphomannomutase activity in patients with CDG1. 11 We have recently identified PMM2, a phosphomannomutase gene on chromosome 16p13. 12 Mutations in this gene in CDG1 patients provide substantial evidence that it is the gene for CDG1. The phosphomannomutase deficiency has now been found in more than 50 CDG1 patients from various geographical origin, 13 and mutations have been identified in a majority of these patients.
14 Thus a direct test is now available for prenatal diagnosis.
Here we report on prenatal diagnosis in eight CDG1 families, thereby showing that phosphomannomutase activities are reduced in amniocytes and trophoblasts of affected foetuses. We would like to spread a cautionary note on the use of linked genetic markers or phosphomannomutase measurements in the prenatal diagnosis of CDG1 in cases in which the diagnosis has not been confirmed by phosphomannomutase measurements or mutation analysis in the proband or in the parents.
Materials and Methods

Linkage Analysis
Polymorphic CA-repeats in the interval between D16S405 and D16S406 were amplified from genomic DNA from lymphocytes, fibroblasts, or cultured amniocytes.
9,10 Markers D16S3020 and D16S3087 have only recently been mapped to the interval between D16S513 and D16S404. 15 
Phosphomannomutase Activities
Phosphomannomutase was assayed spectrophotometrically. 13 In this report, the enzymatic activities are expressed as a percentage of the mean values in controls. Control activities were (means ± SD) 2.46 ± 0.48 mU/mg protein (n = 12) in leukocytes; 3.77 ± 0.86 (n = 8) in fibroblasts; and 6.7 ± 1.0 (n = 3) in amniocytes.
Mutation Analysis of PMM2
Single-strand conformation polymorphism (SSCP) analysis was used to identify mutations in the PMM2 gene, and the underlying base substitutions were identified by sequencing, as described. 12 A complete set of primers for the analysis of PMM2 will be described elsewhere.
14
Results
The proband in family 15 ( Figure 1a ) has a phosphomannomutase deficiency with a value below 0.1 mU/mg protein in fibroblasts (HS in Table 1 in Van Schaftingen and Jaeken).
11 DNA analysis with linked genetic markers on cultured amniocytes revealed that the foetus was not affected but was a heterozygous carrier. Phosphomannomutase measurements on these amniocytes showed intermediate values, compatible with a carrier status. A healthy baby was born, as expected.
In family 37, a crossover within the CDG1 region between D16S414 and D16S407 was observed on the maternal chromosome 16 in the patient (Figure 1b) . Based on published data, the test with the genetic markers was inconclusive. However, the phosphomannomutase measurements showed that the foetus was affected (less than 2% of the normal values) and these data were considered conclusive. This is consistent with more recent mapping data: the PMM2 gene is located between D16S406 and D16S3078 16 (this location is more telomeric than we had previously inferred from association data, 10 and is in accordance with the data from the Scandinavian group. 9, 17 The pregnancy was terminated. Foetal tissue was obtained and assayed for phosphomannomutase: the activity was < 0.05 mU/mg protein in muscle and liver.
In a third family with a phosphomannomutase deficiency in the proband and evidence for linkage to chromosome 16p13 (family 1 in Matthijs et al 10 the proband and foetus have inherited a different paternal chromosome (not shown). However, direct phosphomannomutase measurements on cultured amniocytes revealed low values (20% of mean control values), which could either be interpreted as a (partial) deficiency or a heterozygotic value. As the genetic data are not compatible with a disease state, the latter was withheld. The low values were attributed to the poor growth of amniocytes. The diagnosis in this case thus mostly relied on the genetic data. A healthy baby was born.
In a fourth family, we refrained from offering a prenatal test because fibroblasts from the proband showed normal phosphomannomutase values. The marker data also suggested that linkage to chromosome 16p13 was unlikely (family 18, Figure 1c) . The absence of linkage to the CDG1 locus was confirmed after the birth of a second affected child in this family.
A prenatal diagnosis was offered to three other families with a known phosphomannomutase deficiency (families 2, 9 and 32, data not shown), and in all cases the biochemical and genetic data were consistent. Healthy babies were born (one is predicted to be a carrier). By now, PMM2 mutations have been identified in these families. 14 More recently, prenatal diagnosis was based on the direct mutation analysis of the PMM2 gene in families in which the mutations had been identified. In family 30, the proband has the A108V and the common R141H mutations, as shown by SSCP analysis and confirmed by sequencing. 12 SSCP analysis of DNA isolated from cultured trophoblasts revealed that the foetus had inherited the paternal R141H mutation but not the maternal A108V mutation (Figure 2) . A phosphomannomutase value of 1.2 mU/mg protein was compatible with the carrier status. In family 45, no material was available from the deceased proband. However, phosphomannomutase measurements on leukocytes of the parents revealed that they were carriers, which was confirmed by mutation analysis (data not shown): the father carries the F119L mutation and the mother the R141H mutation, and by deduction, the proband had the F119L/R141H genotype. Both mutations were found in the foetus. Phosphomannomutase values of 0.35 mU/mg protein in cultured amniocytes confirmed the affected status. In family 44, in which the proband did not show a phosphomannomutase deficiency, prenatal testing was not possible.
Discussion
An unfortunate result in prenatal diagnosis was obtained when, a few years ago, Clayton and collaborators used the transferrin assay on foetal blood. 7 Apparently, the IEF pattern is normal in foetal blood and soon after birth, an observation that remains unexplained to date.
In 1994, Martinsson and collaborators mapped the CDG1 candidate region to chromosome 16p13, to a region of 13 cM between markers D16S406 and D16S405. 9 Thus an indirect genetic test became available, based on the analysis of linked markers. However, Figure 2 Direct mutation analysis of the PMM2 gene PCR amplification of exon 4 (left panel) and exon 5 (right panel) of the PMM2 gene, that harbour the A108V and R141H mutations respectively (see 12 ), on genomic DNA from the patient, parents and foetus, was followed by SSCP analysis. The bands associated with the mutation are indicated with an arrowhead. The A108V mutation is of maternal origin in this family. The R141H mutation is inherited from the father. The foetus inherited the paternal disease allele, and is a carrier of the R141H mutation. the observation of genetic heterogeneity for CDG1 10 also jeopardised this assay.
A major breakthrough for CDG1 was the identification of a phosphomannomutase deficiency in patients. 11 In this report, we show that phosphomannomutase is deficient in (cultured) trophoblasts and amniocytes from affected foetuses. In eight families, linkage or mutation analysis was combined with phosphomannomutase measurements of foetal cells. The results suggest that low to intermediate values should be interpreted with caution. Low values were obtained in poorly growing amniocytes in family 1, even though linkage analysis predicted a normal genotype. Note also that there are important variations in the phosphomannomutase values obtained in different cell types from patients with the same genotype. For instance, in fibroblasts from the proband in family 37 (see Figure 1) , activities of up to 27% of normal values were obtained in two independent assays. However, in the amniocytes from the affected foetus in the same family, phosphomannomutase values were virtually zero, whereas both patients share the same genotype. It might well be that the phenotype is partly rescued in cells after prolonged culture of the fibroblasts; however, in no instance have we measured in fibroblasts from patients values above 30% of the normal values.
The problem of interpretation of biochemical data or the risk of recombination between the markers and the mutation is solved by direct mutation analysis, provided that the paternal and maternal mutation have been identified. We presented the results for two such cases. Taken together, we predicted two affected foetuses and three carriers of either a paternal or maternal allele, while the remaining three foetuses did not inherit a disease chromosome. Given the sample size, this is consistent with the autosomal recessive inheritance of the disease. It is now also clear that some patients with the characteristically abnormal IEF pattern of serum transferrins, do not have a phosphomannomutase deficiency ( 13 and the present report). Most likely, however, in all families with a phosphomannomutase deficiency in the proband, there is linkage to the CDG1 locus on chromosome 16p13.
In conclusion, the present results show that prenatal diagnosis for CDG1 can now reliably be made. Our recommendations for the prenatal diagnosis of CDG1 are as follows. One should first determine the phosphomannomutase activity in fibroblasts, leukocytes or lymphocytes of the proband, or if not possible, in leukocytes of the parents, and look for mutations in the PMM2 gene. If no phosphomannomutase deficiency is found, no prenatal diagnosis should be offered at this stage. If a phosphomannomutase deficiency is found and the mutations are identified, the prenatal diagnosis should primarily be based on the detection of mutations. If the mutations are not found, phosphomannomutase measurements should be combined with linkage analysis.
